Three Seasons Wealth LLC Takes $819,000 Position in Roivant Sciences Ltd. $ROIV

Three Seasons Wealth LLC purchased a new position in Roivant Sciences Ltd. (NASDAQ:ROIV) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 29,557 shares of the company’s stock, valued at approximately $819,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in ROIV. Allworth Financial LP raised its position in shares of Roivant Sciences by 48.1% during the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock valued at $27,000 after buying an additional 583 shares in the last quarter. SBI Securities Co. Ltd. lifted its holdings in shares of Roivant Sciences by 1,740.3% during the 4th quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock worth $27,000 after acquiring an additional 1,166 shares during the last quarter. Kestra Advisory Services LLC purchased a new position in Roivant Sciences in the fourth quarter worth $47,000. CIBC Private Wealth Group LLC grew its position in Roivant Sciences by 7,614.3% in the fourth quarter. CIBC Private Wealth Group LLC now owns 2,700 shares of the company’s stock worth $59,000 after acquiring an additional 2,665 shares in the last quarter. Finally, Clearstead Advisors LLC raised its position in Roivant Sciences by 141.6% during the fourth quarter. Clearstead Advisors LLC now owns 2,907 shares of the company’s stock valued at $63,000 after purchasing an additional 1,704 shares in the last quarter. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Insiders Place Their Bets

In other news, Director Melissa B. Epperly sold 17,750 shares of the firm’s stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $34.38, for a total value of $610,245.00. Following the transaction, the director owned 16,474 shares in the company, valued at approximately $566,376.12. This trade represents a 51.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Eric Venker sold 200,000 shares of Roivant Sciences stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $33.16, for a total transaction of $6,632,000.00. Following the completion of the transaction, the chief executive officer directly owned 1,613,063 shares in the company, valued at approximately $53,489,169.08. The trade was a 11.03% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 2,055,913 shares of company stock valued at $68,567,633 in the last ninety days. Company insiders own 10.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on ROIV shares. Leerink Partners set a $42.00 price target on Roivant Sciences in a research note on Thursday, May 21st. Weiss Ratings lowered Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a research report on Friday, May 22nd. TD Cowen raised their price objective on Roivant Sciences from $38.00 to $41.00 and gave the company a “buy” rating in a report on Thursday, May 21st. Citigroup boosted their target price on Roivant Sciences from $35.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, May 21st. Finally, Piper Sandler reaffirmed an “overweight” rating on shares of Roivant Sciences in a research note on Thursday, May 21st. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Roivant Sciences currently has a consensus rating of “Moderate Buy” and an average price target of $33.59.

Roivant Sciences Stock Down 0.1%

Roivant Sciences stock opened at $34.89 on Thursday. The company has a market capitalization of $25.10 billion, a PE ratio of -58.15 and a beta of 1.11. The firm has a fifty day simple moving average of $31.45 and a two-hundred day simple moving average of $28.04. Roivant Sciences Ltd. has a twelve month low of $10.90 and a twelve month high of $37.00.

Roivant Sciences (NASDAQ:ROIV) last announced its quarterly earnings data on Wednesday, May 20th. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.57. Roivant Sciences had a negative return on equity of 20.54% and a negative net margin of 3,629.19%.The firm had revenue of $2.52 million for the quarter, compared to analysts’ expectations of $3.41 million. During the same period last year, the firm earned ($0.29) earnings per share. As a group, equities analysts expect that Roivant Sciences Ltd. will post -1.83 earnings per share for the current fiscal year.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.